Meseclazone  (Synonyms: W2395; NSC297623)

Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.

Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration^[1]. Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs caused a dose-dependent inhibition of bronchoconstriction resulting in the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

239.66

C₁₁H₁₀ClNO₃

29053-27-8

O=C1N(OC(C)C2)C2OC3=CC=C(Cl)C=C13

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. Thromb Haemost. 1978 Aug 31;40(1):24-36.  [Content Brief]

  [2]. Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. Pharmacology. 1982;24(4):243-7.  [Content Brief]